Pacific Biosciences of California (PACB) said Thursday it has appointed Chris Smith, chief executive of NeoGenomics (NEO), to the board of directors, effective immediately.
Smith has extensive experience in the life sciences and healthcare industries and led growth and innovation at NeoGenomics in precision medicine, Pacific Biosciences said.
The company said David Meline is resigning from its board, effective immediately, after contributing to the company's strategy since 2023.
Shares of Pacific Biosciences were up 1.9% and NeoGenomics rose 2.8% in recent trading.
Price: 1.59, Change: +0.03, Percent Change: +1.92